Effect of a single dose of salmeterol on the increase in airway eosinophils induced by allergen challenge in asthmatic subjects.
BACKGROUND
The long acting beta2 agonist salmeterol is very effective in preventing asthmatic responses to specific stimuli, and this effect could theoretically be due to some anti-inflammatory property in addition to bronchodilator property.


METHODS
The protective effect of a single dose of salmeterol (50 microg) on allergen induced early and late responses and on the associated airway inflammation was investigated in a double blind, placebo controlled, crossover study in 11 atopic asthmatic subjects. Eosinophil percentages and concentrations of eosinophil cationic protein (ECP) in peripheral blood and in hypertonic saline induced sputum were measured 24 hours after allergen inhalation.


RESULTS
Salmeterol effectively inhibited both early and late asthmatic responses in comparison with placebo. Salmeterol also inhibited the increase in the percentage of eosinophils in the sputum 24 hours after allergen inhalation (median (range) baseline 6% (1-36), after placebo 31% (5-75), after salmeterol 12% (1-63)). However, the increase in both sputum and serum ECP concentrations 24 hours after allergen challenge was not affected by pretreatment with salmeterol.


CONCLUSIONS
A single dose of salmeterol inhibits the allergen induced airway responses and the increase in sputum eosinophils after allergen challenge.
Dente
F L
FL
Cardio-Thoracic Department, Pneumology Section, University of Pisa, Pisa, Italy.
Bancalari
L
L
Bacci
E
E
Bartoli
M L
ML
Carnevali
S
S
Cianchetti
S
S
Di Franco
A
A
Giannini
D
D
Vagaggini
B
B
Testi
R
R
Paggiaro
P L
PL
D000293:Adolescent; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage* / Q000627:therapeutic use; D000328:Adult; D000420:Albuterol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000704:Analysis of Variance; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology; D001798:Blood Proteins / Q000032:analysis; D001985:Bronchial Provocation Tests; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D047091:Eosinophil Granule Proteins; D004804:Eosinophils / Q000187:drug effects* / Q000473:pathology; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D018836:Inflammation Mediators / Q000097:blood; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D012260:Ribonucleases; D000068299:Salmeterol Xinafoate; D013183:Sputum / Q000276:immunology*; D018709:Statistics, Nonparametric
D000318:Adrenergic beta-Agonists; D001798:Blood Proteins; D047091:Eosinophil Granule Proteins; D018836:Inflammation Mediators; D000068299:Salmeterol Xinafoate; D012260:Ribonucleases; D000420:Albuterol